OncoMatch/Clinical Trials/NCT05692024
COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
Is NCT05692024 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule. for colorectal cancer.
Treatment: Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule. — This is research study is assessing the effects of 6-g daily use of freeze-dried instant coffee on liver fat and fibrosis and the gut microbiome and metabolome in patients who have completed routine treatment (including surgery, chemotherapy and radiotherapy) for stage I-III colorectal cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Disease stage
Required: Stage I, II, III
Prior therapy
Must have received: surgery — standard treatment
have completed standard treatment (including surgery, chemotherapy and radiotherapy) at least 2 months ago
Must have received: chemotherapy — standard treatment
have completed standard treatment (including surgery, chemotherapy and radiotherapy) at least 2 months ago
Must have received: radiation therapy — standard treatment
have completed standard treatment (including surgery, chemotherapy and radiotherapy) at least 2 months ago
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05692024 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received surgery and chemotherapy.
What disease stage is eligible?
Stage I or II or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages